Bone mineral density, bone markers, and fractures in adult males with congenital adrenal hyperplasia

European Journal of Endocrinology

Volumn 168, Issue 3, 2013, Pages 331-341

  Falhammar, Henrik ^a,b   Nyström, Helena Filipsson ^c   Wedell, Anna ^a,b   Brismar, Kerstin ^a,b   Thorén, Marja ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BIOLOGICAL MARKER; CORTISONE ACETATE; DEXAMETHASONE; GLUCOCORTICOID; HYDROCORTISONE; HYDROXYPROGESTERONE; OSTEOCALCIN; PREDNISOLONE; PROLACTIN; SOMATOMEDIN C; STEROID 21 MONOOXYGENASE; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; CALCIUM HOMEOSTASIS; CONGENITAL ADRENAL HYPERPLASIA; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYP21A2 GENE; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY DIAGNOSIS; FEMUR NECK; FRACTURE; GENE; GENOTYPE; HORMONAL REGULATION; HORMONE DEFICIENCY; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; VITAMIN D DEFICIENCY;

ADRENAL HYPERPLASIA, CONGENITAL; ADULT; AGED; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; COHORT STUDIES; FRACTURES, BONE; GENETIC ASSOCIATION STUDIES; GLUCOCORTICOIDS; HORMONE REPLACEMENT THERAPY; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; MUTATION; OSTEOCALCIN; OSTEOPOROSIS; PREVALENCE; STEROID 21-HYDROXYLASE; SWEDEN; YOUNG ADULT;

EID: 84874089603     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0865     Document Type: Article

References (41)

1. Merke DP & Bornstein SR. Congenital adrenal hyperplasia. Lancet 2005 365 2125-2136. (doi:10.1016/S0140-6736(05) 66736-0)
2. Falhammar H & Thoren M. Clinical outcomes in the management of congenital adrenal hyperplasia. Endocrine 2012 41 355-373. (doi:10.1007/s12020- 011-9591-x)
3. Shaker JL & Lukert BP. Osteoporosis associated with excess glucocorticoids. Endocrinology and Metabolism Clinics of North America 2005 34 341-356, viii-ix. (doi:10.1016/j.ecl.2005.01.014)
4. Arisaka O, Hoshi M, Kanazawa S., Numata M, Nakajima D, Kanno S., Negishi M, Nishikura K, Nitta A., Imataka M et al. Preliminary report: effect of adrenal androgen and estrogen on bone maturation and bone mineral density. Metabolism 2001 50 377-379. (doi:10.1053/meta.2001.21678)
5. Girgis R & Winter JS. The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 1997 82 3926-3929. (doi:10.1210/jc.82.12.3926)
6. Fleischman A, Ringelheim J, Feldman HA & Gordon CM. Bone mineral status in children with congenital adrenal hyperplasia. Journal of Pediatric Endocrinology and Metabolism 2007 20 227-235. (doi:10.1515/JPEM.2007.20.2.227)
7. Zimmermann A, Sido PG, Schulze E, Al Khzouz C, Lazea C, Coldea C & Weber MM. Bone mineral density and bone turnover in Romanian children and young adults with classical 21-hydroxylase deficiency are influenced by glucocorticoid replacement therapy. Clinical Endocrinology 2009 71 477-484. (doi:10.1111/j.1365-2265.2008.03518.x)
8. Cameron FJ, Kaymakci B, Byrt E.A., Ebeling PR, Warne GL & Wark JD. Bone mineral density and body composition in congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 1995 80 2238-2243. (doi:10.1210/jc.80.7.2238)
9. de Almeida Freire PO, de Lemos-Marini SH, Maciel-Guerra AT, Morcillo AM, Matias Baptista MT, de Mello MP & Guerra G Jr. Classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a cross-sectional study of factors involved in bone mineral density. Journal of Bone and Mineral Metabolism 2003 21 396-401. (doi:10.1007/s00774-003-0434-6)
10. Paganini C, Radetti G, Livieri C., Braga V, Migliavacca D & Adami S. Height, bone mineral density and bone markers in congenital adrenal hyperplasia. Hormone Research 2000 54 164-168. (doi:10.1159/000053253)
11. Guo CY, Weetman AP & Eastell R. Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia. Clinical Endocrinology 1996 45 535-541. (doi:10.1046/j.1365-2265.1996.00851.x)
12. Mora S, Saggion F, Russo G., Weber G, Bellini A, Prinster C & Chiumello G. Bone density in young patients with congenital adrenal hyperplasia. Bone 1996 18 337-340. (doi:10.1016/8756-3282(96)00003-8)
13. Stikkelbroeck NM, Oyen WJ, van der Wilt GJ, Hermus AR & Otten BJ. Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 2003 88 1036-1042. (doi:10.1210/jc.2002-021074)
14. Christiansen P, Molgaard C & Muller J. Normal bone mineral content in young adults with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hormone Research 2004 61 133-136. (doi:10.1159/000075588)
15. Jaaskelainen J & Voutilainen R. Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21-hydroxylase deficiency. Clinical Endocrinology 1996 45 707-713. (doi:10.1046/j.1365-2265. 1996.8620871.x)
16. Hagenfeldt K, Martin Ritzen E, Ringertz H, Helleday J & Carlstrom K. Bone mass and body composition of adult women with congenital virilizing 21-hydroxylase deficiency after gluco-corticoid treatment since infancy. European Journal of Endocrinology 2000 143 667-671. (doi:10.1530/eje.0.1430667)
17. Sciannamblo M, Russo G, Cuccato D., Chiumello G & Mora S. Reduced bone mineral density and increased bone metabolism rate in young adult patients with 21-hydroxylase deficiency. Journal of Clinical Endocrinology and Metabolism 2006 91 4453-4458. (doi:10.1210/jc.2005-2823)
18. King JA, Wisniewski AB, Bankowski B.J., Carson KA, Zacur HA & Migeon CJ. Long-term corticosteroid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 2006 91 865-869. (doi:10.1210/jc.2005-0745)
19. Falhammar H, Filipsson H, Holmdahl G., Janson PO, Nordenskjold A, Hagenfeldt K & Thoren M. Fractures and bone mineral density in adult women with 21-hydroxylase deficiency. Journal of Clinical Endocrinology and Metabolism 2007 92 4643-4649. (doi:10.1210/jc.2007-0744)
20. Bachelot A, Chakhtoura Z, Rouxel A., Dulon J & Touraine P. Hormonal treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Annales d'Endocrinologie 2007 68 274-280. (doi:10.1016/j.ando.2007.06.019)
21. Arlt W, Willis DS, Wild S.H., Krone N., Doherty EJ, Hahner S, Han TS, Carroll P.V., Conway GS, Rees DA et al. Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. Journal of Clinical Endocrinology and Metabolism 2010 95 5110-5121. (doi:10.1210/jc.2010-0917)
22. Koetz KR, Ventz M, Diederich S & Quinkler M. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. Journal of Clinical Endocrinology and Metabolism 2012 97 85-92. (doi:10.1210/jc. 2011-2036)
23. Nermoen I, Bronstad I, Fougner K.J., Svartberg J., Oksnes M, Husebye ES & Lovas K. Genetic, anthropometric and metabolic features of adult Norwegian patients with 21-hydroxylase deficiency. European Journal of Endocrinology 2012 167 507-516. (doi:10.1530/EJE-12-0196)
24. Finkielstain GP, Kim MS, Sinaii N, Nishitani M., Van Ryzin C, Hill SC, Reynolds J.C., Hanna RM & Merke DP. Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 2012 97 4429-4438. (doi:10.1210/jc.2012-2102)
25. Falhammar H, Filipsson Nystrom H, Wedell A & Thoren M. Cardiovascular risk, metabolic profile, and body composition in adult males with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. European Journal of Endocrinology 2011 164 285-293. (doi:10.1530/EJE-10-0877)
26. Falhammar H, Nystrom HF, Ekstrom U, Granberg S., Wedell A & Thoren M. Fertility, sexuality and testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia. European Journal of Endocrinology 2012 166 441-449. (doi:10.1530/EJE-11-0828)
27. Liddle GW. Clinical pharmacology of the anti-inflammatory steroids. Clinical Pharmacology and Therapeutics 1961 2 615-635.
28. Bang P, Eriksson U, Sara V., Wivall IL & Hall K. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinologica 1991 124 620-629.
29. Hilding A, Hall K, Wivall-Helleryd IL, Saaf M., Melin AL & Thoren M. Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects. Journal of Clinical Endocrinology and Metabolism 1999 84 2013-2019. (doi:10.1210/jc. 84.6.2013)
30. Holick MF. Vitamin D deficiency. New England Journal of Medicine 2007 357 266-281. (doi:10.1056/NEJMra070553)
31. Chakhtoura Z, Bachelot A, Samara-Boustani D, Ruiz J.C., Donadille B., Dulon J, Christin-Maitre S, Bouvattier C, Raux-Demay MC, Bouchard P et al. Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency. European Journal of Endocrinology 2008 158 879-887. (doi:10.1530/EJE-07-0887)
32. Shibli-Rahhal A & Schlechte J. The effects of hyperprolactinemia on bone and fat. Pituitary 2009 12 96-104. (doi:10.1007/s11102-008-0097-3)
33. Zaidi M, Buettner C, Sun L & Iqbal J. Minireview: the link between fat and bone: does mass beget mass? Endocrinology 2012 153 2070-2075. (doi:10.1210/en.2012-1022)
34. Bang P, Degerblad M, Thoren M., Schwander J, Blum W & Hall K. Insulin-like growth factor (IGF) I and II and IGF binding protein (IGFBP) 1, 2 and 3 in serum from patients with Cushing's syndrome. Acta Endocrinologica 1993 128 397-404.
35. Zhou X, Loke KY, Pillai C.C., How HK, Yap HK & Lee KO. IGFs and IGF-binding proteins in short children with steroid-dependent nephrotic syndrome on chronic glucocorticoids: changes with 1 year exogenous GH. European Journal of Endocrinology 2001 144 237-243. (doi:10.1530/eje.0.1440237)
36. Short KR, Nygren J, Bigelow ML & Nair KS. Effect of short-term prednisone use on blood flow, muscle protein metabolism, and function. Journal of Clinical Endocrinology and Metabolism 2004 89 6198-6207. (doi:10.1210/jc. 2004-0908)
37. Donaldson LJ, Reckless IP, Scholes S, Mindell JS & Shelton NJ. The epidemiology of fractures in England. Journal of Epidemiology and Community Health 2008 62 174-180. (doi:10.1136/jech.2006. 056622)
38. Khosla S, Amin S & Orwoll E. Osteoporosis in men. Endocrine Reviews 2008 29 441-464. (doi:10.1210/er.2008-0002)
39. Frisen L, Nordenstrom A, Falhammar H., Filipsson H, Holmdahl G, Janson P.O., Thoren M., Hagenfeldt K, Moller A & Nordenskjold A. Gender role behavior, sexuality, and psychosocial adaptation in women with congenital adrenal hyperplasia due to CYP21A2 deficiency. Journal of Clinical Endocrinology and Metabolism 2009 94 3432-3439. (doi:10.1210/jc.2009-0636)
40. van Rossum EF & van den Akker EL. Glucocorticoid resistance. Endocrine Development 2011 20 127-136.
41. Speiser PW, Azziz R, Baskin L.S., Ghizzoni L., Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori V.M., Oberfield SE et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2010 95 4133-4160. (doi:10.1210/jc.2009-2631)